Stryker price target raised to $250 from $220 at Canaccord

Canaccord analyst Kyle Rose raised the firm’s price target on Stryker to $250 from $220 and keeps a Hold rating on the shares. The analyst said they delivered a strong Q4 despite continued supply chain, inflationary, and FX headwinds, beating on the top and bottom lines.